Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: An analysis of 891 cases

Cancer

Volumn 85, Issue 7, 1999, Pages 1537-1546

  Lai, Chyong Huey ^a,b   Hong, Ji Hong ^a   Hsueh, Swei ^a   Ng, Koon Kwan ^a   Chang, Ting Chang ^a   Tseng, Chih Jen ^a   Chou, Hung Hsueh ^a   Huang, Kuan Gen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adjuvant chemotherapy; Adjuvant radiotherapy; Cervical carcinoma; Pretreatment variables; Prognostic factors

Indexed keywords

CISPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RADICAL HYSTERECTOMY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; CHEMOTHERAPY, ADJUVANT; FEMALE; FLOW CYTOMETRY; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PELVIS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 0033120677     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990401)85:7<1537::AID-CNCR15>3.0.CO;2-6     Document Type: Article

References (30)

1. Kenneth DH, Fu YS. Cervical and vaginal cancer. In: Berek JS, Adashi EY, Hillard PA, editors. Novak's Gynecology. 12th edition. Baltimore, MD: Williams & Willkins, 1996:1111-53.
2. Landoni F, Maneo A, Lolombo A, Placa F, Milani R, Perego P, et al. Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-40.
3. Hsu CT, Chen YS, Su SC. Prognosis of uterine cervical cancer with extensive lymph node metastases. Am J Obstet Gynecol 1972;114:954-62.
4. Piver MS, Chung WS. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol 1975;46:507-10.
5. Boyce JG, Fruchter RG, Nicastri AAD, Roberta HD, Ambiavagar PC, Reinis M, et al. Vascular invasion in stage I carcinoma of the cervix. Cancer 1984;53:1175-80.
6. Delgado G, Bundy BN, Fowler WC, Stehman FB, Sevin B, Creasman WT, et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;35:314-20.
7. Zreik TG, Chambers JT, Chambers SK. Parametrial involvement, regardless of nodal status: a poor prognostic factor for cervical cancer. Obstet Gynecol 1996;87:741-6.
8. Lai CH, Hsueh S, Huang MY, Chang MF, Soong YK. The uses and limitations of DNA flow cytometry in stage IB or II cervical carcinoma. Cancer 1993;72:3655-62.
9. Hogan WM, Littman P, Griner L, Miller CL, Mikuta JJ. Results of radiation therapy given after radical hysterectomy. Cancer 1982;49:1278-85.
10. Kinney WK, Alvarez RD, Reid GC, Schray MF, Soong SJ, Morley GW, et al. Value of adjuvant whole-pelvic irradiation therapy after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a match-control study. Gynecol Oncol 1989;34:258-62.
11. Sivanesaratnam V, Jayalakshmi P. Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage Ib cervical cancer. Cancer 1989;64:798-800.
12. Lai CH, Lin TS, Soong YK, Chen SF. Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma. Gynecol Oncol 1989;35:193-8.
13. Ng HT, Yuan CC, Kan YY, Ho ESC, Yen MS, Chao KC. An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases. Arch Gynecol Obstet 1995;256:1-4.
14. Morrow CP. Is pelvic radiation beneficial in the postoperative management of stage Ib squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy? Gynecol Oncol 1980;10:105-10.
15. Schorage JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AF. Stage Ib and IIa cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol Oncol 1997;66:31-5.
16. Tattersall MHN, Ramirez C, Coppleson M. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases. Gynecol Oncol 1992;46:176-81.
17. Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol 1996;61:3-10.
18. Lai CH, Tang SG, Hsueh S, ChangTC, Tseng CJ, Chou HH, et al. Implications of a failed trial of postoperative adjuvant therapy after radical hysterectomy for stage Ib-IIa cervical carcinoma with pelvic node metastases. Chang Gung Med J 1998;21:291-9.
19. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 1974;44:265-70.
20. Lai CH, Chang HC, Chang TC, Hsueh S, Tang SG. Prognostic factors and impacts of adjuvant therapy in early-stage cervical carcinoma with pelvic node metastases. Gynecol Oncol 1993;51:390-6.
21. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika 1965;52:203-23.
22. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
23. Cox DR, Oakes D. Analysis of survival data. Vol 5. London: Chapman and Hall, 1984:445-6.
24. Barter JF, Soong SJ, Shingleton HM, Hatch KD, Orr JW. Complications of combined radical hysterectomy-postoperative radiation therapy in women with early-stage cervical cancer. Gynecol Oncol 1989;32:292-6.
25. Harrell FE, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med 1984;3:143-52.
26. Byar DP. Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ, editors. Cancer clinical trials methods and practice. Oxford: Oxford University Press, 1984:423-43.
27. Hricak H, Lacey CG, Sandles LG, Chang YCF, Winkler ML, Stern JL. Invasive cervical carcinoma: Comparison of MR imaging and surgical finding. Radiology 1988; 166:623-31.
28. Lai CH, Wang JR, Huang HJ, ChangTC, TsengCH, Chou HH, et al. Recurrent cervical carcinoma after primary radical surgery [abstract P005]. Sixth biennial meeting of the International Gynecologic Cancer Society, Fukuoka, Japan. Int J Gynecol Cancer 1997;7S:33.
29. Sardi JE, Giaroli A, Sananes C, Ferrera M, Soderini A, Bermudez NG, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997;67:61-9.
30. Harrel FE, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problem, and suggested solution. Cancer Treat Rep 1985;69:1071-7.